Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
Open accessThe DOI matches its Crossref record.
Abstract
APX001 is a first-in-class, intravenous (IV) and oral (PO) broad-spectrum antifungal agent in clinical development for the treatment of invasive fungal infections (IFIs) due to Candida, Aspergillus and rare molds. The active moiety APX001A inhibits Gwt1, an early step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Excellent in vivo efficacy has been demonstrated in murine models of IFIs with APX001A AUC0-24 target exposures ~ 80 µg.hours/mL. Eight subjects in Cohort 1a were randomized in a 6:2 ratio to receive APX001 or placebo. Single doses of IV 200 mg were infused over 3 hours followed by single (tablet) doses of 100, 300, and 500 mg, each separated by a 14-day washout period. Ten subjects in Cohort 1b were randomized in a 8:2 ratio to receive either APX001 or placebo. A single PO (tablet) dose of 400 mg was administered under fed and fasted conditions, each separated by a 14-day washout period. MAD Cohorts 2 and 3 were comprised of eight subjects randomized in a 6:2 ratio to receive APX001 or placebo. Subjects received PO (tablet) doses of 500 and 1000 mg daily for 14 days. Pharmacokinetic (PK) parameters for APX001A in plasma were calculated using non-compartmental analysis. Safety monitoring and intense PK sampling occurred throughout the trial. A safety committee reviewed the PK and safety data to determine dose escalation steps. Plasma exposure to APX001A was linear, dose proportional with low intersubject variability and a half-life of ~2.5 days. Accumulation of APX001A was observed in the MAD cohorts. After 14 days of dosing at 500 and 1000 mg AUC0-24 were 192 and 325 µg.hours/mL, respectively. The oral bioavailability was >90%. Administration of APX001 with a high fat, high calorie meal had no effect on the rate or extent of absorption. APX001 was well tolerated across all doses with no clinically significant adverse events observed. All subjects completed dosing. There were no dose limiting toxicities. Most of the adverse events (AEs) were mild, transient and required no treatment. The most common AE was headache. APX001 given orally is highly bioavailable, has no food effect and can exceed target exposures of APX001A for efficacy against Candida and Aspergillus at doses that are safe and well tolerated. M. R. Hodges, Amplyx Pharmaceuticals: Employee, Salary; E. Ople, Amplyx Pharmaceuticals Inc.: Employee, Salary; K. J. Shaw, Amplyx Pharmaceuticals Inc.: Employee, Salary; R. Mansbach, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee; S. P. Van Marle, PRA Health Sciences: Employee, Salary; E. J. Van Hoogdalem, PRA Health Sciences: Employee, Salary; W. Kramer, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee; P. Wedel, Amplyx Pharmaceuticals Inc.: Employee, Salary
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“All AEs were, again, mild, transient, and required no specific treatment with headache that most frequently observed [103].”
BackgroundShaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
Self-citationIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
Self-citationIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Self-citationAlkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97
“Fosmanogepix (APX001) is a broad-spectrum first-in-class small-molecule antifungal that is currently in clinical development for the treatment of invasive fungal infections (9).”
BackgroundResultSelf-citation
Metadata
- Authors
- Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. P., Van Hoogdalem, E.-J., Kramer, W., & Wedel, P.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017
- Volume
- 4
- Issue
- suppl_1
- Pages
- S534-S534
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W2746687770
- Cited by
- 45
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability. https://app.cochat.ai/papers/10.1093/ofid/ofx163.1390
- The paper
- Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. P., Van Hoogdalem, E.-J., Kramer, W., & Wedel, P. (2017). Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofx163.1390
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.